Hemophilia B

The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.